Introduction
============

Cytomegaloviruses are beta-herpesviruses which establish life-long infections in their hosts. Several findings have implicated CD13, also known as aminopeptidase N (APN), in human cytomegalovirus (HCMV) infection and pathogenesis. In a series of bone marrow transplant patients, CD13/APN-specific autoantibodies were found only in patients with confirmed CMV disease after transplant and were highly associated with later development of chronic graft vs. host disease (cGVHD) ([@bib39], [@bib40]). Patients seropositive for CMV but negative for the presence of virus did not develop anti-CD13/APN antibodies or cGVHD ([@bib40]). On the molecular level, several groups have shown that human CMV incorporates host cell proteins, one of which is CD13/APN, into its viral envelope ([@bib18], [@bib27], [@bib28], [@bib48]). Some monoclonal antibodies raised against CD13/APN can neutralize human CMV viral particles, and immunoblots of purified human CMV virions detect CD13/APN ([@bib37]). When viral particles are labeled with immunogold-anti-CD13 antibodies, the immunogold particles are later seen on the surface of infected cells ([@bib13]). Consistent with viral sequestration of CD13/APN, cell surface CD13/APN is down-regulated after human CMV infection in fibroblasts ([@bib33]). Association of CD13/APN with the viral particle has been suggested as a mechanism for the generation of anti-CD13/APN antibodies after CMV infection by autoimmunization ([@bib28]). That virus-associated CD13/APN is essential for HCMV infection is suggested by anti-CD13 antibody inhibition of infection ([@bib37]); however, human neuroblastoma cells lacking CD13 expression were susceptible to HCMV infection ([@bib46]), and recently the epidermal growth factor receptor has been shown to be an important mediator of HCMV entry into cells ([@bib45]).

CD13/APN is a membrane-bound metalloproteinase widely expressed on mammalian cells including monocytes, macrophages, endothelial cells, epithelial cells, and fibroblasts ([@bib10], [@bib33], [@bib34], [@bib36]). It exists as a heavily glycosylated homodimer with a constitutively active proteinase activity external to the plasma membrane ([@bib36]). In addition to numerous tissue-specific functions, CD13/APN serves as a major receptor for type I coronaviruses ([@bib6], [@bib49]), including possibly the SARS virus ([@bib50]). More recently, CD13/APN has been shown to be an important mediator of angiogenesis when expressed on endothelial cells of nascent blood vessels ([@bib4]). Antibodies raised against CD13/APN and inhibitors of aminopeptidase activity both block angiogenesis in models of neovascularization ([@bib32]). This may have significance with regard to CMV, since CMV infection is associated with many chronic vascular diseases ([@bib5], [@bib15], [@bib29], [@bib31]). CMV-induced anti-CD13/APN antibodies may represent one mechanism by which the virus initiates vascular pathology.

Like most herpesviruses, cytomegaloviruses are species specific, but the link between CMV and vascular disease seen in humans has been reproduced repeatedly in mice infected with murine cytomegalovirus ([@bib3], [@bib14], [@bib19], [@bib35]). Therefore, in this study, we have examined whether CD13/APN is also implicated in MCMV infections in mice.

Results
=======

MCMV infection induces anti-CD13/APN antibodies in a strain-specific manner
---------------------------------------------------------------------------

Four mouse strains were tested for the induction of MCMV and CD13/APN immunity after MCMV infection. These strains, CBA, CBAxC57BL/6 f1 hybrids, ICR, and 129S mice deficient in the interferon gamma receptor (IFNgR−/−), vary in their H-2 haplotype and in their reported resistance to MCMV infection. Groups of 4--6 animals of each of these strains were infected with 10^5^ PFU MCMV by IP injection, which is a sublethal dose in adult animals for all strains. Serum was collected after 14 days and analyzed by ELISA for IgG antibodies against MCMV and mouse CD13/APN. All strains had similar levels of IgG antibodies directed against MCMV ([Fig. 1](#fig1){ref-type="fig"} ). However, anti-CD13/APN antibodies were detected only in the sera from ICR and 129S-IFNgR−/− mice, and no detectable antibodies against CD13 were found in sera from CBA or B6 hybrid mice. Anti-CD13 antibodies in humans were reported in people who developed HCMV viremia while in an immunocompromised state. In order to test whether an immunocompromised state would be associated with induction of higher levels anti-CD13 antibodies in mice, cyclosporine A was used to induce an immunocompromised state in ICR mice. Three groups of 6 ICR mice were treated with either cyclosporine A alone, cyclosporine A and 10^5^ PFU MCMV, or 10^5^ PFU MCMV + mock cyclosporine A injections. Mice treated with cyclosporine A and MCMV had increased signs of illness over those given MCMV alone (not shown). However, levels of antibodies to both MCMV and CD13 were not significantly different between the two groups ([Fig. 2](#fig2){ref-type="fig"} ).Fig. 1MCMV infection induces anti-CD13 antibodies in susceptible strains of mice. Groups of four ICR, CBA/J, B6/CBA f1 hybrids, and interferon gamma receptor knock out mice on a 129S background were infected by intraperitoneal injection with 10^5^ PFU MCMV. Sera collected 14 days post-infection were assayed in duplicate at a 1:10 dilution for anti-MCMV (gray bars) and anti-CD13 (black bars) antibodies by ELISA. Figure is representative of two similar experiments. Dashed line indicates mean antibody response in mock-infected mice.Fig. 2Effect of cyclosporine A treatment on anti-CD13 antibody induction by MCMV infection. Sera from female ICR mice were analyzed for anti-MCMV (gray bars) and anti-CD13 (black bars) IgG antibodies by ELISA. Groups of 6 mice were injected with (1) cyclosporine A (CsA) once daily for 15 days, (2) diluent once daily for 15 days and inoculation with 10^5^ pfu MCMV-*lac*Z on day 2, (3) CsA daily for 15 days and an equivalent amount of uninfected salivary gland extract on day 2. All treatments were by intraperitoneal injection. Sera were collected on day 15, diluted 1:10 in saline, and analyzed in duplicate. Results are expressed as fold increase in antibody levels relative to the mean response of mice treated with CsA alone.

Cell surface APN activity and MCMV susceptibility
-------------------------------------------------

To investigate whether expression of murine CD13/APN correlates with MCMV susceptibility as reported for HCMV ([@bib37], [@bib38]), five murine cell lines were characterized with respect to MCMV progeny production and cell surface aminopeptidase N/CD13 activity. NIH 3T3, 3T12, and primary mouse embryonic fibroblasts (MEF) are all fibroblast in phenotype. Py-41 and SVEC-4 cells are mouse endothelial cell lines immortalized by the polyoma T antigen and the SV40 T-antigen, respectively ([@bib11], [@bib30]). In an assay of MCMV progeny production after inoculation at low multiplicity of infection, marked differences were seen between cell lines in susceptibility to productive MCMV infection ([Fig. 3](#fig3){ref-type="fig"}A). Peak MCMV titers in supernatants from the three fibroblast lines were close to 10^6^ PFU/ml, while SVEC-4 cells produced 10^5^ PFU/ml, and Py-41 cells produced less than 1000 PFU/ml. Similar relative results were seen in a plaque assay on the five cell lines ([Fig. 4](#fig4){ref-type="fig"} ).Fig. 3Characterization of five murine cell lines with respect to MCMV progeny production and cell surface aminopeptidase N/CD13 activity. (A) Monolayers of murine endothelial cell lines Py-41 and SVEC-4, and murine fibroblast cell lines 3T3 and 3T12, and primary embryonic fibroblasts (MEF), were infected with salivary gland-derived MCMV-*lac*Z at an MOI of 0.1. Aliquots of supernatant collected approximately every 24 h were tittered on 3T3 fibroblasts. Data shown are combined results of two independent experiments. (B) Measurement of cell surface aminopeptidase N activity by ala-*p*-nitroalanine cleavage. Actively growing cells of each type were plated at four different densities 16 h prior to incubation with colorimetric APN substrate ala-*p*-nitroalanine. Each data point is the average of absorbance readings of 6 wells after 3-h incubation at 37 °C.Fig. 4MCMV susceptibility does not correlate with cell surface aminopeptidase N/CD13 activity. Five murine cell lines (Py-41, SVEC-4, 3T3, 3T12) and primary embryonic fibroblasts (MEF) were each seeded into wells of a 96-well plate at 10,000 cells/well. After being allowed to adhere overnight, six wells of each cell type were immediately assayed for cell surface APN activity, and parallel wells of each cell type were exposed to MCMV-*lac*Z virus. After 2-h incubation with virus, inoculum was replaced with fresh medium. Two days later, plaques were visualized by X-Gal overlay. The titer (light bars) is expressed as mean plaques per well. Relative APN activity (dark bars) is indicated in absorbance units on the right *y*-axis. The figure is representative of two identical experiments.

In contrast to human cells, attempts to compare CD13/APN expression on murine cell lines by immunological methods were unsuccessful. Two commercially available antibodies specific for murine CD13/APN failed to recognize any proteins on Western blotted cell extracts (not shown). Immunofluorescent flow cytometry staining of cell surface proteins with antibody R3-242 conjugated to phycoerythrin showed that CD13/APN was present on both endothelial and fibroblast cells. However, relative expression cannot be compared by this method in different cell types, so an alternative to immunological techniques was used.

To quantitate cell surface CD13/APN, APN enzymatic activity was measured by a standard procedure using the colorimetric substrate, ala-*p*-nitroanalide hydrochloride ([@bib34]). To determine the linearity of the assay with adherent cells, Py-41, SVEC-4, 3T3, 3T12, and MEF cells were plated at densities of 5000, 10,000, 20,000, and 40,000 cells/well and incubated 18 h later as adherent monolayers with APN substrate. Substrate conversion was directly proportional to the number of cells in all cell lines ([Fig. 3](#fig3){ref-type="fig"}B), with slight decreases at higher densities as expected. Cells were plated at 10,000 cells/well in 96-well plates for subsequent assays. To compare amounts of cell-surface CD13/APN exposed to MCMV in a standard inoculation with subsequent plaque formation, parallel sets of 6 wells of each cell type were assayed for APN enzyme activity, or inoculated with MCMV-*lac*Z and incubated a further 48 h, followed by staining and counting of plaques. Three dilutions of MCMV-*lac*Z virus were used in three sets of 6 wells to detect the range of susceptibilities observed. There was no correlation between CD13/APN expression and MCMV plaque formation ([Fig. 4](#fig4){ref-type="fig"}). CD13/APN enzyme activity was similar on all five cell lines whereas plaque formation and progeny virus production were markedly different, especially between endothelial and fibroblast cells. Whether or not CD13/APN is necessary for MCMV infection cannot be determined from this experiment since none of the murine cell lines tested were negative for CD13/APN, however, CD13 expression is clearly not sufficient for productive MCMV infection of Py-41 endothelial cells.

APN inhibitors reduce MCMV infection
------------------------------------

EDTA and 1,10-phenanthroline monohydrate are both APN inhibitors which act by chelating divalent metals. At effective concentrations, both have the effect of causing adherent cells, such as 3T3 cells, to lift. Therefore, cells were purposely incubated with MCMV-*lac*Z virus in suspension in the presence or absence of APN inhibitor. After 1-h incubation, cells were washed clean of unbound virus and inhibitor and plated. Plaques visualized at 48 h post-infection with X-Gal were counted in 6 parallel wells/treatment. Both EDTA and 1,10-phenanthroline significantly decreased the number of plaques formed on treated cells in a dose-dependent manner ([Fig. 5](#fig5){ref-type="fig"}A). Exposure to concentrations of 1,10-phenanthroline above 1.5 mM or EDTA above 5 mM for 1 h killed 3T3 cells. In contrast, when virus was exposed to the same inhibitor concentrations for 30 min prior to dilution and inoculation of cells, little effect was seen on plaque formation, indicating that the MCMV particles themselves were not dependent on metalloproteinase activity for stability or activity ([Fig. 5](#fig5){ref-type="fig"}B).Fig. 5APN inhibitors reduce MCMV infection, but not virus viability. (A) NIH 3T3 cells (6 × 10^4^) were incubated in suspension with MCMV-*lac*Z plus or minus APN inhibitors (10 mM, 5 mM, 1 mM or 0.1 mM EDTA, or 3 mM, 1.5 mM, 0.5 mM, or 0.17 mM 1,10-phenanthroline) or antibodies (R3-242, sc-15360) as indicated. After 30 min at 37 °C, cells were washed and resuspended in complete medium, and seeded at 10^4^ cells/well into 6 wells of a 96-well plate. Plaques were visualized in each well by X-Gal overlay 72 h post-infection. ++ Indicates cytotoxic inhibitor concentration. \* indicates a significant difference from untreated control. (B) Virus pretreatment with APN inhibitors: 10^5^ PFU MCMV-*lac*Z were incubated with inhibitors or anti-CD13 antibodies as indicated for 30 min, diluted 300-fold, and used to infect NIH 3T3 cells (6 × 10^4^/100 μl) in suspension. Plaques were visualized as in A. A representative of three similar experiments is shown.

Effect of anti-CD13/APN antibody on MCMV infection in vitro
-----------------------------------------------------------

CD13/APN has been detected with antibodies in HCMV viral envelopes and some anti-CD13/APN antibodies neutralize human CMV and prevent infection in vitro ([@bib13]). Both anti-murine CD13/APN antibodies were tested for their ability to block MCMV infection of NIH3T3 cells. Neither preincubation of antibody with virus nor antibody with host cells reduced plaque formation ([Figs. 5](#fig5){ref-type="fig"}A and B). Since not all CD13/APN epitopes give rise to neutralizing antibodies of HCMV ([@bib13]), this did not rule out a role for APN in MCMV infection. Strangely, the presence of antibody R3-242 during infection significantly enhanced the number and size of plaques formed on NIH3T3 cells ([Fig. 5](#fig5){ref-type="fig"}A), while antibody H-300 had a similar effect when preincubated with virus ([Fig. 5](#fig5){ref-type="fig"}B). Although antibody-dependent enhancement of viral infection is well documented, it generally requires antibodies from the same species as the host cells and depends on Fc or complement receptor expression of the host cell ([@bib43]). R3-242 and H-300 are rat and rabbit antibodies, respectively, and NIH 3T3 cells are not known to express Fc receptors.

Two other methods were used to attempt to detect APN incorporation into MCMV viral particles. APN activity assays of salivary gland-derived virus vs. uninfected salivary gland supernatants were compared and found to be identical when normalized for protein content ([Table 1](#tbl1){ref-type="table"} ). In addition, salivary gland-derived MCMV, tissue culture-derived MCMV, relevant uninfected control extracts, and murine brush border membrane vesicles (BBMV) were spotted onto nitrocellulose at several dilutions and probed with antibody R3-242. The antibody readily detected an 80-fold dilution of BBMV, while failing to detect any protein in the viral or control preparations at any dilution (data not shown). In summary, no evidence for incorporation of CD13/APN into MCMV viral envelopes was found.Table 1APN activity in MCMV virus preparationAPN activity (substrate cleaved/mg protein)BBMV (μmol/min)53.7Uninfected salivary gland homogenate (μmol/min)3.0MCMV-infected salivary gland homogenate (μmol/min)2.8

Cell surface CD13/APN activity is not significantly altered by MCMV infection
-----------------------------------------------------------------------------

Human CMV has been reported to reduce CD13/APN expression in infected human fibroblasts approximately 30% within 24 h of infection, as determined by immunofluorescence staining and APN activity assays. Expression is further reduced to up to 50% over the next 2--3 days of infection and appears to be due to ER retention and degradation of the CD13 protein ([@bib33]). To determine if MCMV has a similar effect on murine CD13/APN, cells from all five murine cell lines were assayed for APN activity 18 and 72 h after infection. Cells were infected with an MOI of approximately 20, or mock infected with an equivalent concentration of salivary gland homogenate from uninfected mice. In contrast to human fibroblasts, all three mouse fibroblast lines had slightly (10--30%) increased APN cell surface activity 18 h after infection, while mouse endothelial cell lines Py-41 and SVEC-4 had slightly (3--9%) decreased APN activity ([Fig. 6](#fig6){ref-type="fig"} ). At 72 h, cell death was apparent in all infected wells, and APN activity was reduced compared to mock-infected wells, however, APN activity per well was increased compared to 18 h post-infection in all cases due to increases in cell number (not shown). Whole cell ELISA gave similar results, except that differences between infected and non-infected cells were even smaller (not shown). Therefore, unlike human CMV infection, MCMV infection seems to have only a small effect if any on CD13/APN expression in fibroblasts and endothelial cells, which varies according to cell type.Fig. 6Cell surface APN activity is not significantly altered by MCMV infection. Parallel wells of each cell line were mock infected (gray bars) or infected with MCMV-*lac*Z at an MOI of 10 (black bars). After 18 h of infection, cell surface APN activity was measured by ala-*p*-nitroalanine cleavage. Addition of APN inhibitor 1,10-phenanthroline (striped bars) with substrate was used as a positive control.

Discussion
==========

In agreement with previous reports that human CMV infection induces anti-CD13/APN antibodies in immunocompromised individuals, we found that murine CMV induced antibodies against murine CD13/APN in susceptible strains of mice. However, treatment of susceptible mice with the immunosuppressant Cyclosporine A did not significantly increase anti-CD13/APN antibody production, suggesting that immunosuppression is not necessary for induction of these autoantibodies. Whether immunocompetent humans can develop anti-CD13 antibodies after CMV infection has not been investigated to our knowledge.

The strain producing the highest ratio of anti-CD13 to anti-MCMV antibodies was 129S-IFNgR−/− which has been used as a model of persistent CMV infection because the mice actively shed virus for at least 6 months after infection ([@bib35]). In contrast, CBA and CBA/B6 hybrids are known to be genetically resistant to MCMV-induced mortality. MCMV resistance in mice is determined largely by the gene *cmv1*, which encodes Ly49H, an NK cell receptor which is activated by the MCMV protein m157 ([@bib1], [@bib23], [@bib42]). MCMV-resistant mouse strains have peak spleen viral titers that are 2--3 logs lower and LD~50~ doses that are 1--2 logs higher than susceptible strains. CBA and C57BL/6 mice express Ly49H on their NK cells and are resistant whereas 129S mice do not express Ly49H and are susceptible. The ICR mice were not genotyped for cmv1 and were intermediate in their susceptibility to MCMV morbidity, as well as autoantibody production. This suggests that high spleen titers may be associated with development of anti-CD13 antibodies. MHC type does not seem to be correlated with anti-CD13 antibody production in our experiments, since the haplotype H-2^b^ is shared by both productive 129S and non-productive C57BL/6 hybrid strains.

In the human system, it has been proposed that anti-CD13/APN antibodies occur as a result of autoimmunization by CD13/APN incorporated into HCMV viral envelopes. We were unable to find evidence of CD13/APN incorporation into MCMV viral particles, but this may be due to the limited variety of anti-CD13 antibodies available for the murine system. Neither antibody tested was able to detect CD13/APN on Western blots, and sc-15360 failed to detect CD13/APN even in native BBMV containing APN readily detected at a 1:80 dilution by antibody R3-242. It is possible that a more comprehensive array of anti-murine CD13/APN antibodies would have detected CD13/APN in MCMV particles or have been able to neutralize MCMV infectivity, however, APN enzymatic assays also failed to detect a difference between virus and control lysates. Cell-surface CD13/APN also did not correlate with MCMV susceptibility. And while inhibitors of APN enzyme activity did reduce MCMV plaque formation, the inhibitors used are not especially specific for APN. Taken together, a role for CD13/APN as an entry mediator for MCMV seems unlikely.

Virus-induced autoantibodies, including anti-endothelial cell and anti-phospholipid antibodies following cytomegalovirus infections, have been demonstrated before in both mice and humans ([@bib2], [@bib9], [@bib12], [@bib16], [@bib17], [@bib24], [@bib25]). With regard to the mechanisms of their induction, it has been proposed that these antibodies are directed against viral antigens which by coincidence resemble host cellular proteins (molecular mimicry), or that virus-induced tissue damage results in immunological processing and recognition of self-antigens normally sequestered from immune surveillance ([@bib22], [@bib28]). In this study, several factors argue against a simple case of molecular mimicry. Although human and mouse CD13/APN are 76% identical at the amino acid level ([@bib8]), HCMV and MCMV share less homology, CD13/APN is glycosylated and genetically polymorphic ([@bib44], [@bib47]), and predicted MHC presentable peptides differ with MHC haplotype and species. Therefore, the likelihood of a single epitope common to both hosts, both viruses, and presentable by several MHC types seems small. Determination of the CD13/APN epitopes recognized by the sera of different mouse strains is currently underway and may allow identification of a viral antigen inducer if molecular mimicry is leading to the production of anti-CD13/APN antibodies.

Immunological processing of self-antigens as a result of virus-induced tissue damage is more difficult to examine. The association of CD13/APN autoantibodies with conditions favoring high in vivo titers is consistent with this mechanism. However, CD13/APN cannot credibly be described as a sequestered self-antigen in that it is normally expressed on the surface of numerous cell types throughout the body and is present in normal serum ([@bib20]). Therefore, neither of the general mechanisms thought to give rise to virus-induced autoantibodies seems likely in the case of MCMV-induced CD13/APN antibodies.

CMV seropositivity has long been associated with a variety of vasculopathies including atherosclerosis and systemic sclerosis ([@bib5], [@bib15], [@bib29], [@bib31]). CMV infection has also long been recognized as a serious complication of bone marrow and solid organ transplantation because of vascular sequelae ([@bib5], [@bib26]). CMV viremia after bone marrow transplant is associated with a significant increase in chronic graft vs. host disease (cGVHD), which shares many features in common with the autoimmune disease scleroderma, and begins as an inflammation and destruction of small blood vessels ([@bib31]). CMV viremia after solid organ transplant results in exacerbation of transplant vascular sclerosis leading to chronic graft rejection ([@bib5]). The mechanism(s) by which CMV produces these negative outcomes is not understood, however, reduction of viral titers with anti-viral drugs decreases cGVHD, CMV-associated rejection, and vascular stenosis ([@bib21], [@bib26]). Autoantibodies targeting an angiogenic factor such as CD13/APN may be one mechanism by which CMV could mediate these effects. The two mouse strains found to produce anti-CD13/APN antibodies in this study are also the strains most susceptible to CMV-induced vascular disease ([@bib3], [@bib14], [@bib35]). The fact that CMV induction of anti-CD13/APN antibodies is now reproduced in mice should make it possible to examine whether such antibodies play a part in CMV-induced vascular pathology.

Materials and methods
=====================

Cells, medium, antibodies, FACS, immunoblotting
-----------------------------------------------

SVEC-4, NIH 3T3, and NIH 3T12 cells were obtained from the ATCC (Rockville, MD) and grown as recommended. Mouse embryo fibroblasts were prepared from Balb/c mouse embryos as described ([@bib7]). Py-41 cells were generously provided to our lab by V.L. Bautch (University of North Carolina, Chapel Hill, NC) and propagated on gelatin-coated plates (Biocoat, Becton Dickenson) in low glucose DMEM + 10% fetal calf serum ([@bib11]). All cells were grown in medium containing Gibco antibiotic--antimycotic solution (Invitrogen, Inc.). Two anti-murine CD13 antibodies were used: R3-242, a rat anti-mouse monoclonal (Research Diagnostics, Inc.), and sc-15360, a rabbit IgG (Santa Cruz Biotechnologies, Inc.).

Virus and plaque assays
-----------------------

A recombinant murine cytomegalovirus expressing the *Escherichia coli lac*Z gene (RM461), generously provided by Edward Mocarski (Stanford University), was used in all experiments. This virus expresses *lac*Z mid to late infection so that the enzyme accumulates throughout infection ([@bib41]). Salivary gland passaged virus was prepared as described previously ([@bib14]) and titered on 3T3 cells. Plaque assays were performed in 96-well plates. Briefly, NIH 3T3 cells were plated the day before the assay at 10^4^ cells/well. Dilutions of virus were made in minimal essential medium containing 0.1% porcine gelatin, and 20 μl diluted virus/well was incubated with cells at 37 °C for 2 h. Inoculum was aspirated and cells covered with 100 μl/well 0.6% methylcellulose in complete medium. After incubation for 48--72 h, 100 μl 10% neutral-buffered formalin was added to each well for 10 min, followed by three washes with phosphate-buffered saline to remove methylcellulose. Plaques were visualized by overlay with X-Gal (5-bromo-4-chloro-3-indolyl-beta-[d]{.smallcaps}-galactopyranoside) and counted under a dissecting scope. Inoculations of mice were by intraperitoneal injection of salivary gland-passaged virus in a volume of 0.2 ml using minimal essential medium as a diluent.

Reagents
--------

Cyclosporine A was purchased from LC laboratories (Woburn, MA) and 14 mg was solubilized in 0.5 ml 100% ethanol and 0.2 ml Tween 80, then diluted to 2 mg/ml in PBS for injection. Ethylenediaminetetraacetic acid (0.5 M solution, pH 8.0) was purchased from GibcoBRL (Cat. No. 15575-038). 1,10-Phenanthroline monohydrate (P 9375) and [l]{.smallcaps}-alanine-*p*-nitroanilide hydrochloride were purchased from Sigma.

Mice
----

CBA, CBA/C57BL6 f1 hybrids, and 129S IFNgR−/− mice were obtained from Jackson Laboratories (Bar Harbor, Maine). ICR mice were purchased from Harlan Laboratories. All experiments described in this study conform with "The guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the MUSC institutional committee for the care and use of laboratory animals. Food and water were provided ad libitum. All mice were housed in hepa-filtered cages in the approved animal facility and monitored daily.

Crude aminopeptidase N preparation
----------------------------------

To prepare murine CD13, small intestines from nine ICR mice were dissected free of mesenteric fat and flushed clean with cold saline. The drained tissue was homogenized in 9 volumes cold sucrose buffer (2 mM Tris, pH 6.8, 50 mM sucrose) with a Tissumizer SDT-1810 (Tekmar, Cincinnati OH) for 1 min keeping the tube on ice. Brush border membrane vesicle formation was induced by adding CaCl~2~ to a final concentration of 10 mM and stirring continuously for 15 min at 4 °C. Debris was pelleted by centrifugation at 4000 × *g* for 10 min. BBMVs were pelleted by centrifugation of the supernatant for 30 min at 27,000 × *g* at 4 °C. BBMVs were resuspended in a small volume of sucrose buffer and stored at −80 °C. Gut APN has been shown to be serologically identical to CD13/APN expressed in splenocytes and macrophage ([@bib36]).

Aminopeptidase N activity assays
--------------------------------

Aminopeptidase N activity assays were performed by incubating living adherent cells at 37 °C in phosphate-buffered saline (pH 7.2) containing 6 mM alanine-*p*-nitoanilide hydrochloride. Absorbance was read at 1-h intervals at 405 nm.

ELISA
-----

ELISAs were performed on Reacti-Bind maleic anhydride activated clear 96-well plates (Pierce, Rockford, IL). Viral antigen for ELISA was intact MCMV grown in tissue culture and prepared by ultracentrifugation through sucrose by standard protocol ([@bib7]). The partially purified virus was diluted in phosphate-buffered saline to a protein concentration of 10 mg/ml and plates were coated using 50 μl/well overnight at 4 °C. For detection of anti-CD13/APN antibodies, BBMVs in sucrose buffer were diluted in PBS to a protein concentration of 1.5 mg/ml, and 50 μl/well was used to coat plates overnight at 4 °C. Blocking of binding of rabbit antibody sc-15360 and rat monoclonal R3-242 by mouse sera demonstrated specificity of antibodies in sera of MCMV-infected mice for CD13/APN. Whole cell ELISAs were also performed to measure cell surface CD13 expression on the murine cell lines. Cells were plated at 10^4^ cells/well and incubated with R3-242 anti-CD13 antibody the next day after fixation with 2% glutaraldehyde. Horseradish peroxidase-conjugated secondary antibodies were used and detected by incubation with 1-Step ABTS (Pierce).
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